Baidu
map

Circulation:急性心梗后阿司匹林剂量对治疗效果的影响

2015-05-25 MedSci MedSci原创

    背景  阿司匹林是广泛使用于心肌梗死(MI)抗血小板的药物,但其经皮冠状动脉介入治疗(PCI)术最佳的维持剂量仍存在不确定性。    方法和结果  研究人员比较了在2010-2012年间在TRANSLATE-ACS研究中228家美国医院的10213名经历了PCI的心梗患者,并在出院后进行双重抗血小板治疗的结果。主要不良心血管事件(

背景  阿司匹林是广泛使用于心肌梗死(MI)抗血小板的药物,但其经皮冠状动脉介入治疗(PCI)术最佳的维持剂量仍存在不确定性。
 
方法和结果  研究人员比较了在2010-2012年间在TRANSLATE-ACS研究中228家美国医院的10213名经历了PCI的心梗患者,并在出院后进行双重抗血小板治疗的结果。主要不良心血管事件(MACE)和出院后6个月的出血量按照阿司匹林高剂量(325毫克)和阿司匹林低剂量(81毫克)进行了比较,并利用回归模型逆概率加权调整进行了分析。总体而言,6387例患者(63%)出院后接受大剂量的阿司匹林治疗。 MACE风险在组间没有显著不同(高 VS 低:未经调整的8.2% VS 9.2%;调整后的危险比为0.99,95%置信区间[Cl]0.85-1.17)。高剂量阿司匹林的使用与任何出血学术研究联合会(BARC)定义的出血事件更大的风险相关(未经调整的24.2% VS 22.7%;调整后的比值比[OR]1.19,95%Cl 1.06-1.33),这主要是由较小的BARC 1型或2型不需要住院出血事件造成的(未经调整的21.4% VS 19.5%;调整后的OR 1.19,95% Cl 1.05-1.34)。需要住院治疗的出血事件在阿斯匹林剂量组相似(未经调整的2.8% VS 3.2%,调整OR 1.22,95%Cl 0.87-1.70)。类似的相关性在具有里程碑意义的阿斯匹林剂量随时间的变化的分析中也被观察到,整个亚组的分析是通过年龄,性别,基线阿司匹林使用,以及ADP受体抑制剂(氯吡格雷与普拉格雷/替卡格雷)类型得到的。
 
结论  在PCI治疗的心梗患者中,高阿司匹林维持剂量与MACE率相似,但与出院后低剂量阿司匹林治疗患者相比,高剂量治疗患者在轻微出血方面有更大的风险。
 
原始出处
 
Ying Xian1*; Tracy Y. Wang1; Lisa A. McCoy1; Mark B. Effron2; Timothy D. Henry3; Richard G. Bach4; Marjorie E. Zettler2; Brian A. Baker5; Gregg C. Fonarow6; Eric D. Peterson1,The Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Study,Circulation,2015.5.20

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053385, encodeId=1d88205338581, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Aug 25 16:21:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893896, encodeId=cf2f189389668, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Wed Sep 16 20:21:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25219, encodeId=40f12521965, content=冼教授好厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=183.62.37.**, createdTime=Thu May 28 23:12:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308324, encodeId=ac8c130832498, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed May 27 02:21:00 CST 2015, time=2015-05-27, status=1, ipAttribution=)]
    2015-08-25 lfyang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053385, encodeId=1d88205338581, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Aug 25 16:21:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893896, encodeId=cf2f189389668, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Wed Sep 16 20:21:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25219, encodeId=40f12521965, content=冼教授好厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=183.62.37.**, createdTime=Thu May 28 23:12:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308324, encodeId=ac8c130832498, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed May 27 02:21:00 CST 2015, time=2015-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053385, encodeId=1d88205338581, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Aug 25 16:21:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893896, encodeId=cf2f189389668, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Wed Sep 16 20:21:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25219, encodeId=40f12521965, content=冼教授好厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=183.62.37.**, createdTime=Thu May 28 23:12:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308324, encodeId=ac8c130832498, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed May 27 02:21:00 CST 2015, time=2015-05-27, status=1, ipAttribution=)]
    2015-05-28 183.62.37.**

    冼教授好厉害啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2053385, encodeId=1d88205338581, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Aug 25 16:21:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893896, encodeId=cf2f189389668, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Wed Sep 16 20:21:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25219, encodeId=40f12521965, content=冼教授好厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=183.62.37.**, createdTime=Thu May 28 23:12:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308324, encodeId=ac8c130832498, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed May 27 02:21:00 CST 2015, time=2015-05-27, status=1, ipAttribution=)]

相关资讯

NEJM:长期应用替格瑞洛 显著降低既往心梗患者不良事件发生率

既往心梗患者长期使用替格瑞洛双抗血小板疗法,短期内的疗效已经被证实,但一年或者更长时间以后的效果仍未充分确立,大样本的数据研究更为缺乏。近日,一项发表于国际杂志New England Journal of Medicine上的研究论文借助大样本群体研究,证实了长期随访下替格瑞洛双抗的远期效果和安全性。替格瑞洛同氯吡格雷一样,属于P2Y12受体抑制剂,但是和前者稍有不同的是,替格瑞洛 属于可逆P2Y

NEJM:心梗患者长期使用替卡格雷效果好坏参半

    超过1年的心肌梗死后双重抗血小板治疗的潜在益处尚未建立。在这方面,我们研究替卡格雷的有效性和安全性,一种急性冠状动脉综合征之后既定功效的P2Y12受体拮抗剂。    我们随机分配,以双盲1:1:1的方式,21162例服用替卡格雷90毫克的剂量1至3年前每天两次有过心肌梗塞,替卡格雷为60毫克的剂量,每天两次,或安慰剂。所有患者均接受低剂量阿司匹林,并

1例跌宕起伏的急性胸痛病例,心梗吗?

急性胸痛是急诊内科最常见的疾病。调查发现,急性胸痛在门诊接诊的患者中占20%,在救护车接诊的患者中占69%,在急诊室接诊的患者中占45%。对于急性 胸痛首先应明确是否由潜在致死性疾病引起,如急性心肌梗死(AMI)、主动脉夹层(AD)、急性肺栓塞和张力性气胸等,需要在短时间内作出恰当诊断和处 理。若误诊或漏诊,会导致严重后果。 【病例简介】 [入院情况] 患者男性,49岁,

NEJM:CTA检查不能改善冠脉疾病(CAD)治疗效果

背景:很多病人发生冠心病(CAD)之前会出现先兆症状,尽管通过随机试验得出诊断的数据很少,但大家普遍通过使用诊断性操作判断评估患者病情。方式:我们随机选取10003位出现冠心病先兆症状的患者接受冠状动脉CT血管造影(CTA)(我们称之为实验组)或功能性测试(使用运动心电图、核压力测试、负荷超声心动图)(我们称之为对照组)进行试验。我们关注的主要指标是患者死亡率、心肌梗塞和因不稳定性心绞痛住院、出现

Circulation:ST段抬高心梗年轻病人中的性别差异

为了将健康的结果最大化,对ST段抬高的心肌梗死病人进行早期再灌注治疗是很必须的。在过去的数十年中,许多研究已经记录了ST段抬高心肌梗死病人再灌注治疗的性别差异。女性患者更有可能在治疗过程中遭遇拖延病人无法接受到合适的治疗。但是,这些拖延对于年轻女性(小于55岁)的程度和影响仍知之甚少,这部分是因为女性中这种疾病发病率较低以及研究的有限的代表性。 耶鲁大学的研究人员调查了再灌注治疗的比例和类型的性

Circulation:冠脉搭桥手术后的病人长期服用β受体阻滞剂有无必要?

对于正在行冠状动脉旁路移植术(冠脉搭桥,CABG)的患者,术后长期应用β受体阻滞剂的必要性和有效性一直争议不断。最近的一些观察性研究也显示出了相矛盾的结果。出院后病人要不要长期服药,这让心外的医师在写出院医嘱时困惑不已。到底CABG病人出院后需不需要长期服用β受体阻滞剂?来自于中国北京协和医院和阜外心血管病医院的研究者们最近在Circulation杂志发表了一篇文章,针对这个问题给出了证据充足的回

Baidu
map
Baidu
map
Baidu
map